Epirubicin (CAS 56420-45-2)

Epirubicin, an anthracycline antineoplastic agent, has been extensively studied in scientific research for its mechanism of action and potential applications in cancer biology and chemotherapy. This compound exerts its cytotoxic effects by intercalating into DNA strands, inhibiting topoisomerase II activity, and inducing DNA strand breaks, ultimately leading to cell cycle arrest and apoptosis in proliferating cells. Researchers have utilized epirubicin as a tool to investigate cancer cell biology, tumor heterogeneity, and drug resistance mechanisms. Studies have focused on elucidating the molecular pathways involved in epirubicin-induced cytotoxicity, as well as identifying predictive biomarkers for patient response to anthracycline-based chemotherapy regimens. Furthermore, epirubicin has been employed in research to evaluate its efficacy in various cancer models, including breast, ovarian, and lung cancers. Beyond cancer research, epirubicin has found applications in studies investigating drug delivery systems, nanoparticle formulations, and novel drug combinations to enhance its efficacy and minimize off-target toxicity. With ongoing advancements in cancer biology and drug development, epirubicin remains a valuable tool in scientific investigations aimed at understanding tumor biology.